M

Myungmoon Pharm Co Ltd
KRX:017180

Watchlist Manager
Myungmoon Pharm Co Ltd
KRX:017180
Watchlist
Price: 1 829 KRW -1.14%
Market Cap: 62.1B KRW

Relative Value

The Relative Value of one Myungmoon Pharm Co Ltd stock under the Base Case scenario is hidden KRW. Compared to the current market price of 1 829 KRW, Myungmoon Pharm Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Myungmoon Pharm Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
79
vs Industry
88
Median 3Y
0.4
Median 5Y
0.5
Industry
2.6
vs History
0
vs Industry
28
Median 3Y
11.4
Median 5Y
-10
Industry
21.4
vs History
11
vs Industry
30
Median 3Y
-10.5
Median 5Y
-10.7
Industry
16.4
vs History
vs Industry
34
Median 3Y
-9.9
Median 5Y
-9.4
Industry
22.8
vs History
77
vs Industry
73
Median 3Y
0.8
Median 5Y
1
Industry
2.2
vs History
79
vs Industry
80
Median 3Y
0.9
Median 5Y
1
Industry
2.9
vs History
77
vs Industry
81
Median 3Y
1.6
Median 5Y
1.9
Industry
5.5
vs History
38
vs Industry
18
Median 3Y
14.8
Median 5Y
11
Industry
13
vs History
33
vs Industry
6
Median 3Y
19.2
Median 5Y
-10.4
Industry
16.5
vs History
9
vs Industry
16
Median 3Y
-22.9
Median 5Y
-16.3
Industry
15.6
vs History
vs Industry
11
Median 3Y
-23.1
Median 5Y
-20.1
Industry
18.7
vs History
79
vs Industry
73
Median 3Y
0.7
Median 5Y
0.8
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Myungmoon Pharm Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Myungmoon Pharm Co Ltd
KRX:017180
61.1B KRW 0.3 50.3 11.7 18.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.2 108.4 158.7
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.5 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14.1 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
KR
M
Myungmoon Pharm Co Ltd
KRX:017180
Average P/E: 27.2
50.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
37%
0.8
CH
Novartis AG
SIX:NOVN
18.5
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
M
Myungmoon Pharm Co Ltd
KRX:017180
Average EV/EBITDA: 400.8
11.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
2
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
M
Myungmoon Pharm Co Ltd
KRX:017180
Average EV/EBIT: 1 713.8
18.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5